Effect of treatment with inosine pranobex in acute respiratory viral infections in children

A.E. Abaturov, A.A. Nikulina, N.M. Tokareva


The scientific review outlines current data on the main provisions of the immunomodulating and antiviral action of inosine pranobex. The article summarizes the results of studies of the clinical efficacy and safety of inosine pranobex for the treatment of children with acute respiratory viral infections caused by Th1-mediated immune response activation and the inhibitory effect on the replication of DNA and RNA of viruses.


inosine pranobex; respiratory-inotropic viruses; children; review


Abaturov AE, Volosovets AP, Yulish EI. The role of Toll-like receptors in the recognition of pathogen-associated molecular structures of infectious pathogens and the development of inflammation. Part 1. Family TLR. Zdorovʹe rebenka. 2012;(40):116-121. (in Russian).

Bulgakova VA, Balabolkin II, Sedova MS, et al. Clinical and immunological efficacy of Inosine pranobex for acute respiratory infections in children with atopic asthma. Pediatricheskaya Farmakologiya. 2010;7(3):98-105. (in Russian).

Bulgakova VA. Acute respiratory tract infections: widening of possibilities of antiviral treatment. Voprosy Sovremennoi Pediatrii. 2013;12(5):74-79. (in Russian).

Bulgakova VA. Original preparation of Inosine pranobeх for etiopathogenetic therapy of acute respiratory viral infections. Uchastkovyi pediatr. 2014;(5):22-23. (in Russian).

Dronov IA, Geppe NA, Malakhov AB, Kolosova NG. Inosin pranobeх: possibilities of etiotropic therapy in acute respiratory infection in children. Clinical Practice in Pediatrics. 2016;11(4):39-43. (in Russian).

Eliseeva MIu, Tsarev VN, Masikhi KN, еt al. The effectiveness of auxiliary immunotherapy in patients with immunodeficiency and frequently ill children: a systematic review and meta-analysis of the use of Inosine pranobex. RMJ. 2010;18(5):313-320. (in Russian).

Erofeeva SB. Isoprinosin: a solution of the problem of polypharmacy in the treatment of influenza and acute respiratory viral infections. Pharmateca. 2015;(313):87-90. (in Russian).

Isakov VA, Isakov DV, Alekseeva EA. Modern possibilities of therapy of respiratory infections. Klinicheskaia farmakologiia i terapiia. 2017;26(5):51-56. (in Russian).

Kramarev SA. Inosine pranobex in the practice of pediatric physician. Paediatrics. Eastern Europe. 2014;(5):70-76. (in Russian).

Kramarev SA, Yevtushenko VV, Golubovskaya OA, Doroshenko VA. Treatment of influenza and other acute respiratory viral infections. Clinical infectology and parasitology. 2014;(11):147-155. (in Russian).

L’vova II, Grishkina LIu, Deriusheva AV, et al. Ostrye respiratornye virusnye infektsii u detei. Diagnostika, lechenie, profilaktika: uchebnoe posobie [Acute respiratory viral infections in children. Diagnosis, treatment, prevention: tutorial]. Perm: PGMA; 2014. 162 p. (in Russian).

Osidak LV, Zarubaev VV, Obraztsova EV, Erman ES, Drinevsky VP. Isoprinosin in therapy of acute respiratory viral infections in frequently ill children. Children's Infections. 2008;7(4):35-40. (in Russian).

Osidak LV, Obraztsova EV. Efficacy of the Inosine pranobex molecule in therapeutic and pediatric practice. Epidemiologia i infekcionnye bolezni. Aktual’nye voprosy. 2012;(4);26-32. (in Russian).

Semenova AR, Tsarenko OE. Morbidity of children of Izhevsk with acute respiratory viral infection for 2014-2015. Theoretical and applied research in the field of natural, humanitarian and technical sciences. Collection of scientific papers. 2015:13-17. (in Russian).

Sergienko EN, Shmeleva NP, Germanenko IG, Gribkova NV. Influenza in children: clinical and epidemiological features and new therapeutic options. Novosti Meditsiny i Farmatsii. 2010;(308):15-17. (in Russian).

Smiyan OI, Bynda ТP, Dmitrova YeV, Sukharieva VA. Current etiopathogenetic and clinical-diagnostic manifestations of acute viral respiratory infections in children. Journal of Clinical and Experimental Medical Research. 2013;1(3):328-336. (in Ukrainian).

Chudakova TK, Romanovskaya AV, Mikhailova EV, Khvorostukhina NF, Tseka YuS. The choice of etiotropic therapy for acute respiratory viral infections in children. Clinical Practice in Pediatrics. 2015;10(5):77-82. (in Russian).

Chudakova TK, Mikhailova EV, Levin DYu, Karal'skiy SA, Koshkin AP. Inosine pranobex in etiotropic therapy of acute respiratory viral infections in frequently ill children. Clinical Practice in Pediatrics. 2016;11(5):62-65. (in Russian).

Chudakova TK, Mikhaylova EV, Shvedova NM. Effectiveness of antiviral therapy for acute respiratory viral infections in frequently ill children. Clinical Practice in Pediatrics. 2015;10(1):58-63. (in Russian).

Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. doi: 10.1186/s12879-016-1965-5.

Bohmwald K, Espinoza JA, Pulgar RA, Jara EL, Kalergis AM. Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus. Front Immunol. 2017 Nov 27;8:1643. doi: 10.3389/fimmu.2017.01643.

Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011;3(3):274-9. doi: 10.1159/000324176.

Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1986 Nov;32(5):383-424. doi: 10.2165/00003495-198632050-00001.

Choi E, Ha KS, Song DJ, Lee JH1, Lee KC. Clinical and laboratory profiles of hospitalized children with acute respiratory virus infection. Korean J Pediatr. 2018 Jun;61(6):180-186. doi: 10.3345/kjp.2018.61.6.180.

Fox A, Le NM, Horby P, et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One. 2012;7(2):e31535. doi: 10.1371/journal.pone.0031535.

Golebiowska-Wawrzyniak M, Markiewicz K, Kozar A, et al. Immunological and clinical study on therapeutic efficacy of inosine pranobex. Pol Merkur Lekarski. 2005 Sep;19(111):379-82. (in Polish).

Hersey P, Bindon C, Bradley M, Hasic E. Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells. Int J Immunopharmacol. 1984;6(4):321-8.

Inosine pranobex. Available from: Accessed: July 29, 2018.

Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163-94. doi: 10.1146/annurev-immunol-032712-100001.

Lasek W, Janyst M, Wolny R, Zapała Ł, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015 Jun;65(2):171-80. doi: 10.1515/acph-2015-0015.

Majewska A, Lasek W, Janyst M, Mlynarczyk G. Inhibition of adenovirus multiplication by inosine pranobex and interferon α in vitro. Cent Eur J Immunol. 2015;40(4):395-9. doi: 10.5114/ceji.2015.56960.

Majewska A, Lasek W, Mlynarczyk G. Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro. Med Dosw Mikrobiol. 2015;67(2):107-13.

Milano S, Dieli M, Millott S, Miceli MD, Maltese E, Cillari E. Effect of isoprinosine on IL-2, IFN-gamma and IL-4 production in vivo and in vitro. Int J Immunopharmacol. 1991;13(7):1013-8.

Moniuszko T, Rogalewska A, Chyrek-Borowska S. The effect of therapy with selected immunomodulators on interleukin-2 production by peripheral blood lymphocytes. Pneumonol Alergol Pol. 1992;60 Suppl 2:120-1.

Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016 Jul;38(4):471-82. doi: 10.1007/s00281-016-0558-0.

Petrova M, Jelev D, Ivanova A, Krastev Z. Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res. 2010 Apr;30(4):223-8. doi: 10.1089/jir.2009.0057.

Schmidt S, Tramsen L, Rais B, Ullrich E, Lehrnbecher T. Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. Oncotarget. 2018 Apr 17;9(29):20891-20907. doi: 10.18632/oncotarget.25058.

Singh H, Herndon DN. Effect of isoprinosine on lymphocyte proliferation and natural killer cell activity following thermal injury. Immunopharmacol Immunotoxicol. 1989;11(4):631-44. doi: 10.3109/08923978909005391.

Tsang KY, Fudenberg HH, Gnagy M.J. Restoration of immune responses of aging hamsters by treatment with Isoprinosine. J Clin Invest. 1983 Jun;71(6):1750-5.

Waldman RH, Ganguly R. Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection. Ann N Y Acad Sci. 1977 Mar 4;284:153-60.

Wong SS, Oshansky CM, Guo XJ, et al. Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study. J Infect Dis. 2018 Jan 4;217(2):245-256. doi: 10.1093/infdis/jix571.

Yoo JK, Kim TS, Hufford MM, Braciale TJ. Viral infection of the lung: host response and sequelae. J Allergy Clin Immunol. 2013 Dec;132(6):1263-76; quiz 1277. doi: 10.1016/j.jaci.2013.06.006.

You Y, Wang L, Li Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015 Jun;42(6):596-601. doi: 10.1111/1346-8138.12845.

Zamora AE, Aguilar EG, Sungur CM, et al. Licensing delineates helper and effector NK cell subsets during viral infection. JCI Insight. 2017 May 18;2(10). pii: 87032. doi: 10.1172/jci.insight.87032.

Zhou G, Juang SW, Kane KP. NK cells exacerbate the pathology of influenza virus infection in mice. Eur J Immunol. 2013 Apr;43(4):929-38. doi: 10.1002/eji.201242620.

Copyright (c) 2020 A.E. Abaturov, A.A. Nikulina, N.M. Tokareva

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта